News
ELAB
0.0201
-30.45%
-0.0088
Elevai Labs announces update and extension of pending offer to exchange shares of common stock
Seeking Alpha · 9h ago
ELEVAI LABS INC. ANNOUNCES UPDATE AND EXTENSION OF PENDING OFFER TO EXCHANGE
Reuters · 9h ago
Weekly Report: what happened at ELAB last week (1028-1101)?
Weekly Report · 19h ago
Dow Jumps 400 Points; US Adds 12,000 Jobs In October
Benzinga · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-Wayfair, B. Riley, Church & Dwight
Reuters · 3d ago
Why Charter Communications Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket
Benzinga · 3d ago
BUZZ-U.S. STOCKS ON THE MOVE-Intel, Abbott, Boeing
Reuters · 3d ago
Why Carvana Shares Are Trading Higher By Around 20%; Here Are 20 Stocks Moving Premarket
Benzinga · 4d ago
Biotech Alert: Searches spiking for these stocks today
TipRanks · 10/28 14:35
Weekly Report: what happened at ELAB last week (1021-1025)?
Weekly Report · 10/28 12:25
12 Consumer Staples Stocks Moving In Friday's Intraday Session
Benzinga · 10/25 16:31
Elevai Labs, Inc.: Correspondence
Press release · 10/25 16:08
Biotech Alert: Searches spiking for these stocks today
TipRanks · 10/23 16:06
Elevai Biosciences engages KCRN Research to support IND efforts for EL-22
TipRanks · 10/22 14:01
Elevai Labs' Elevai Biosciences Engages Leading Contract Research Organization To Support Regulatory Planning Efforts And Pre-IND Meeting With The FDA For EL-22 For The Treatment Of Obesity
Benzinga · 10/22 13:55
ELEVAI BIOSCIENCES, A SUBSIDIARY OF ELEVAI LABS INC., ENGAGES LEADING CONTRACT RESEARCH ORGANIZATION (CRO) TO SUPPORT REGULATORY PLANNING EFFORTS AND PRE-IND MEETING WITH THE FOOD AND DRUG ADMINISTRATION FOR EL-22 FOR THE TREATMENT OF OBESITY
Reuters · 10/22 13:54
Weekly Report: what happened at ELAB last week (1014-1018)?
Weekly Report · 10/21 12:19
Elevai Biosciences highlights past preclinical data on EL-32
TipRanks · 10/21 11:39
ELEVAI BIOSCIENCES, A SUBSIDIARY OF ELEVAI LABS INC., HIGHLIGHTS PAST POSITIVE PRECLINICAL DATA SHOWING POTENTIAL OF EL-32, A DUAL MYOSTATIN & ACTIVIN-A BLOCKER, FOR THE TREATMENT OF OBESITY
Reuters · 10/21 11:30
ELEVAI: EL-32 PRECLINICAL RESULTS SHOWED STATISTICALLY SIGNIFICANT INCREASES IN GRIP STRENGTH, MOTOR FUNCTION & BODY COMPOSITION IN AGED MOUSE MODEL
Reuters · 10/21 11:30
More
Webull provides a variety of real-time ELAB stock news. You can receive the latest news about Elevai Labs, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ELAB
Elevai Labs, Inc. is a physician-dispensed skincare company. The Company conducts research and development to advance science-driven topical skincare that complements the medical aesthetics industry. It produces and commercializes topical skincare products that contain its proprietary stem cell derived Elevai Exosomes designed to enhance the appearance of skin. Its Precision Regenerative Exosome Technology (PREx) biotechnology process yields exosome lots from human umbilical cord-derived mesenchymal stem cells (hUMSC) for its specialty physician-dispensed skincare product lines. It has integrated the use of stem cell exosomes into its initial product line: Elevai Post Treatment E-Series. The E-Series comprises two post-skincare procedure care products that target the face and neck, and upper chest regions. Its products include Empower and Enfinity serums. Empower is its after-treatment topical product that supports the appearance of healthy skin and promotes an even toned complexion.